← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT07634640

NCT07634640 Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07634640
Status Recruiting
Phase EARLY_Phase 1
Sponsor University of Florida
Condition Heart Failure With Preserved Ejection Fraction (HFPEF)
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2023-11-03
Primary Completion 2027-05-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Ferumoxytol infusion

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 70 participants in total. It began in 2023-11-03 with a primary completion date of 2027-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Subjects undergo a gadolinium-based CMR followed by an iron infusion and then a repeat CMR in 72 hours

Eligibility Criteria

Inclusion Criteria: * HFpEF Exclusion Criteria: * Renal insufficiency

Contact & Investigator

Central Contact

Ellen C Keeley, MD, MS

✉ ellen.keeley@medicine.ufl.edu

📞 800-265-0820

Principal Investigator

Ellen C Keeley, MD, MS

PRINCIPAL INVESTIGATOR

University of Florida

Frequently Asked Questions

Who can join the NCT07634640 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Heart Failure With Preserved Ejection Fraction (HFPEF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07634640 trial and what does that mean for participants?

Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.

Is NCT07634640 currently recruiting?

Yes, NCT07634640 is actively recruiting participants. Contact the research team at ellen.keeley@medicine.ufl.edu for enrollment information.

Where is the NCT07634640 trial being conducted?

This trial is being conducted at Gainesville, United States.

Who is sponsoring the NCT07634640 clinical trial?

NCT07634640 is sponsored by University of Florida. The principal investigator is Ellen C Keeley, MD, MS at University of Florida. The trial plans to enroll 70 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology